Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability

Article, Review English OPEN
Kirino, Eiji;
(2012)
  • Publisher: Dove Press
  • Journal: Patient Preference and Adherence,volume 6,pages853-861 (issn: 1177-889X, eissn: 1177-889X)
  • Publisher copyright policies & self-archiving
  • Related identifiers: pmc: PMC3526882, doi: 10.2147/PPA.S22495
  • Subject: SSRI | discontinuation symptoms | R5-920 | Review | Medicine (General) | Patient Preference and Adherence | allosteric action | escitalopram | MDD
    mesheuropmc: behavioral disciplines and activities | mental disorders

Eiji Kirino1,21Department of Psychiatry, Juntendo University Shizuoka Hospital, Shizuoka, Japan; 2Department of Psychiatry, Juntendo University School of Medicine, Tokyo, JapanAbstract: Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®) is a select... View more
  • References (55)
    55 references, page 1 of 6

    1. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5): 343-362.

    2. Sanchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)- enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003;167(4):353-362.

    3. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,Scitalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005;15(2):193-198.

    4. Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology. 2003;45(2): 167-173.

    5. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005;30(7):1269-1277.

    6. Kimura M. Escitalopram oxalate. J Jpn Soc Hosp Pharm. 2012;48: 371-375.

    7. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005;65(16):2379-2404.

    8. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding prolfie of escitalopram and R-ufloxetine. Biol Psychiatry. 2001;50(5):345-350.

    9. Dhillon S, Scott LJ, Plosker GL. Escitalopram: a review of its use in the management of anxiety disorders. CNS Drugs. 2006;20(9):763-790.

    10. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem. 2005;92(1):21-28.

  • Related Organizations (1)
  • Metrics
Share - Bookmark